BillionToOne, Inc. (BLLN) income statement
BLLNNasdaqServices-Medical LaboratoriesFiscal year ends December 31
$89.92−0.28 (-0.31%)
Close on Nov 20, 2026Market cap $4.24BP/E –Yield –
BillionToOne, Inc. financial ratios
See a number that looks wrong?
Close on Nov 20, 2026Market cap $4.24BP/E –Yield –
See a number that looks wrong?
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Margins | ||||
| Gross margin | 68.3% | 53.0% | 24.1% | – |
| Operating margin | 5.3% | -30.9% | -96.9% | – |
| EBITDA margin | 7.5% | -26.3% | -88.7% | – |
| Pre-tax margin | 2.5% | -27.2% | -115.3% | – |
| Net profit margin | 2.4% | -27.2% | -115.3% | – |
| Free cash flow margin | 5.2% | -30.7% | -83.4% | – |
| Effective tax rate | 3.9% | – | – | – |
| Returns on capital | ||||
| Return on equity | 2.6% | 17.7% | 45.8% | – |
| Return on assets | 1.6% | -13.8% | – | – |
| Return on tangible assets | 1.6% | -13.8% | – | – |
| Return on invested capital | -8.8% | 9.5% | – | – |
| Return on capital employed | 3.7% | -17.2% | – | – |
| Return on total capital | 9.5% | 23.6% | – | – |
| NOPAT | $15.39M | -$37.25M | -$54.90M | – |
| Cash flow quality | ||||
| OCF / Sales | 8.1% | -27.1% | -74.8% | – |
| OCF / Net income | 3.30 | 1.00 | 0.65 | – |
| FCF / OCF | 63.9% | 113.1% | 111.5% | – |
| FCF / Net income | 2.11 | 1.13 | 0.72 | – |
| FCF / EBITDA | 68.6% | 116.5% | 94.1% | – |
| Unlevered free cash flow | $15.79M | -$44.89M | -$57.26M | – |
| Levered free cash flow | $15.71M | -$46.78M | -$59.85M | – |
| Efficiency | ||||
| Asset turnover | 0.65 | 0.51 | – | – |
| Fixed asset turnover | 16.28 | 8.92 | – | – |
| Receivables turnover | 9.20 | 6.18 | – | – |
| Days sales outstanding | 39.7 | 59.1 | – | – |
| Payables turnover | 16.83 | 16.65 | – | – |
| Days payables outstanding | 21.7 | 21.9 | – | – |
| Inventory turnover | 7.36 | 8.21 | – | – |
| Days inventory outstanding | 49.6 | 44.5 | – | – |
| Operating cycle | 89.3 | 103.6 | – | – |
| Cash conversion cycle | 67.6 | 81.7 | – | – |
| CapEx to revenue | 2.9% | 3.5% | 8.6% | – |
| CapEx to OCF | 36.1% | -13.1% | -11.5% | – |
| CapEx to depreciation | 1.29 | 0.77 | 1.05 | – |
| Liquidity | ||||
| Current ratio | 11.69 | 8.03 | – | – |
| Quick ratio | 11.32 | 7.72 | – | – |
| Cash ratio | 10.34 | 6.75 | – | – |
| Working capital | $512.60M | $199.43M | – | – |
| Net current asset value | $408.01M | $93.51M | – | – |
| Leverage | ||||
| Total debt | $57.23M | $51.48M | – | – |
| Net debt | -$438.75M | -$140.00M | – | – |
| Debt / Equity | 0.12 | -0.20 | – | – |
| Debt ratio | 9.0% | 17.0% | – | – |
| Assets to equity | 1.32 | -1.20 | – | – |
| Long-term debt to assets | 9.0% | 17.0% | – | – |
| Long-term debt to equity | 0.12 | -0.20 | – | – |
| Total debt / Capitalization | 10.7% | -25.7% | – | – |
| Long-term debt / Capitalization | 10.7% | -25.7% | – | – |
| Net debt / EBITDA | -19.14 | 3.49 | – | – |
| Total debt / EBITDA | 2.50 | -1.28 | – | – |
| Cash flow to debt | 43.0% | -80.4% | – | – |
| Interest coverage | ||||
| EBIT / Interest expense | 168.66 | -19.76 | -21.24 | – |
| EBITDA / Interest expense | 241.29 | -16.83 | -19.44 | – |
| (EBITDA − CapEx) / Interest expense | 147.81 | -19.09 | -21.32 | – |
| Per share | ||||
| Revenue per share | 14.37 | 13.97 | 7.33 | – |
| EPS (basic) | 0.18 | -4.12 | -8.45 | – |
| EPS (diluted) | 0.14 | -4.12 | -8.45 | – |
| Book value per share | 22.61 | -23.03 | -22.39 | – |
| Tangible book value per share | 22.61 | -23.03 | -22.39 | – |
| Cash per share | 23.36 | 17.52 | 9.94 | – |
| Operating cash flow per share | 1.16 | -3.79 | -5.49 | – |
| Free cash flow per share | 0.74 | -4.28 | -6.12 | – |
| CapEx per share | 0.42 | 0.49 | 0.63 | – |
| Valuation at period end | ||||
| Market cap | $914.85M | – | – | – |
| Enterprise value | $719.69M | – | – | – |
| P/E | 123x | – | – | – |
| P/S | 3.0x | – | – | – |
| P/B | 1.9x | – | – | – |
| P/TBV | 1.9x | – | – | – |
| P/Gross profit | 4.4x | – | – | – |
| P/OCF | 37.2x | – | – | – |
| P/FCF | 58.2x | – | – | – |
| EV/Sales | 2.4x | – | – | – |
| EV/Gross profit | 3.5x | – | – | – |
| EV/EBITDA | 31.4x | – | – | – |
| EV/EBIT | 44.9x | – | – | – |
| EV/OCF | 29.3x | – | – | – |
| EV/FCF | 45.8x | – | – | – |
| Earnings yield | 0.81% | – | – | – |
| FCF yield | 1.7% | – | – | – |
| Shareholder yield | ||||
| Buyback yield | 0.00% | – | – | – |
| Debt paydown yield | 0.00% | – | – | – |
| Shareholder yield | 0.00% | – | – | – |
| Cost structure | ||||
| R&D to revenue | 16.2% | 24.0% | 31.2% | – |
| SG&A to revenue | 46.9% | 59.9% | 89.8% | – |
| Stock-based comp to revenue | 5.2% | 5.5% | 6.8% | – |
| Per employee | ||||
| Total employees | 713 | 713 | 713 | 713 |
| Revenue per employee | $427.93K | $214.00K | $100.60K | – |
| Gross profit per employee | $292.37K | $113.49K | $24.27K | – |
| Operating profit per employee | $22.47K | -$66.12K | -$97.47K | – |
| Net income per employee | $10.45K | -$58.30K | -$115.96K | – |
| Free cash flow per employee | $22.04K | -$65.61K | -$83.94K | – |
| Growth | ||||
| Revenue 1Y growth | 100.0% | 112.7% | – | – |
| Gross profit 1Y growth | 157.6% | 367.5% | – | – |
| EBIT 1Y growth | 134.0% | 32.2% | – | – |
| EBITDA 1Y growth | 157.1% | 36.9% | – | – |
| Net income 1Y growth | 117.9% | 49.7% | – | – |
| Diluted EPS 1Y growth | 103.4% | 51.2% | – | – |
| Operating cash flow 1Y growth | 159.4% | 22.9% | – | – |
| Free cash flow 1Y growth | 133.6% | 21.8% | – | – |
| CapEx 1Y growth | 64.4% | -12.5% | – | – |
| Total assets 1Y growth | 109.4% | – | – | – |
| Total equity 1Y growth | 290.8% | -14.9% | -54.5% | – |
Every figure here is calculated from standardized financial statements — hover a row name for the formula — not reported by the company. Valuation multiples use the closing price at the end of that period, not today's price.